Ofloxacin plus Rifampicin versus Doxycycline plus Rifampicin in the treatment of brucellosis: a randomized clinical trial [ISRCTN11871179]

BMC Infectious Diseases

Idris Şahin³  Derya Kayas¹  Irfan Sencan³  Oguz Karabay² 

[1] Department of Internal Medicine, Duzce Social Security Hospital, Duzce, Turkey;Department of Infectious Disease and Clinical Microbiology, Abant Izzet Baysal University Izzet Baysal Medical Faculty Hospital, Bolu/Turkey;Department of Infectious Disease and Clinical Microbiology, Abant Izzet Baysal University Duzce Medical School, Duzce TURKEY

关键词: fever;    quinolone;    doxycycline;    rifampicin;    ofloxacin;    Brucellosis;   

Others  :  1177090
DOI  :  10.1186/1471-2334-4-18

 received in 2003-10-14, accepted in 2004-06-23,  发布年份 2004

【 摘 要 】

Background

The combination therapies recommended by the World Health Organization for treatment of brucellosis are doxycycline plus rifampicin or doxycycline plus streptomycin. Although highly successful results have been obtained with these two regimens, relapse rates as high as 14.4%. The most effective and the least toxic chemotherapy for human brucellosis is still undetermined. The aim of the present study was to investigate the efficacy, adverse effects and cost of ofloxacin plus rifampicin therapy, and doxycycline plus rifampicin therapy and evaluate in the treatment of brucellosis.

Methods

The open trial has been carried out prospectively by the two medical centers from December 1999 to December 2001 in Duzce region Turkey. The diagnosis was based on the presence of signs and symptoms compatible with brucellosis including a positive agglutination titre (≥1/160) and/or a positive culture. Doxycycline and rifampicin group consisted of 14 patients who were given doxycycline 200 mg/day plus rifampicin 600 mg/day during 45 days and this group Ofloxacin plus rifampicin group was consisted of 15 patients who were given ofloxacin 400 mg/day plus rifampicin 600 mg/day during 30 days.

Results

Regarding clinical and/or demographic characteristics no significant difference was found between two groups of patients that underwent two different therapeutic regimens. At the end of the therapy, two relapses were seen in both groups (p = 0.695). Although duration of therapy was two weeks shorter in group treated with rifampicin plus ofloxacin, the cure rate was similar in both groups of examinees. Fever dropped more rapidly in the group that treated with rifampicin plus ofloxacin, 74 ± 30 (ranges 48–216) vs. 106 ± 26 (ranges 48–262) hours (p = 0.016).

Conclusions

Ofloxacin plus rifampicin therapy has advantages of shorter treatment duration and provided shorter course of fever with treatment than in doxycycline plus rifampicin therapy. However, cost of ofloxacin plus rifampicin treatment is higher than doxycycline plus rifampicin treatment. Because of the similar effects, adverse effects and relapses rates between two regimens, we still advice doxycycline plus rifampicin for the treatment of brucellosis for countries, which have limited resources.

【 授权许可】

   
2004 Karabay et al; licensee BioMed Central Ltd. This is an Open Access article: verbatim copying and redistribution of this article are permitted in all media for any purpose, provided this notice is preserved along with the article's original URL.

【 图 表 】

Figure 1.

【 参考文献 】

• [1]Saltoglu N, Tasova Y, Inal SA, Seki T, Aksu HS: Efficacy of rifampicin plus doxycycline versus rifampicin plus quinolone in the treatment of brucellosis. Saudi Med J 2002, 23:921-4.
• [2]Geyik FM, Gur A, Nas K, Cevik R, Sarac J, Dikici B, Ayaz C: Musculoskeletal involvement in brucellosis in different age groups: a study of 195 cases. Swiss Med Wkly 2002, 132:98-105.
• [3]Young JE: Brucella species. In Principles and practice of infectious diseases. Edited by Mandell GL, Dolin R, Benett JE. Churchill Livingstone, New York; 1995:2053-57.
• [4]Ariza J, Gudiol F, Pallares R, Fernandez-Viladrich P, Rufi G, Correddoira J, Miravitiles M: Treatment of human brucellosis with doxycycline plus rifampicin or doxycycline plus streptomycin. Annals of Internal Medicine 1992, 117:25-30.
• [5]Sauret JM, Vilissova N: Human brucellosis. J Am Board Fam Pract 2002, 15:401-6.
• [6]Stastical annual of Turkey Republic T.C Government Statically Instuty 1993, 118-120.
• [7]Solera J, Martinez-Alfaro E, Espinosa A: Recognition and optimum treatment of brucellosis. Drugs 1997, 53:245-56.
• [8]Gobernado M, Canton E, Santos M: In vitro activity of ciprofloxacin against Brucella melitensis. Eur Journal of Clin Microbiol & Infect Dis 1984, 3:371.
• [9]Baykal M, Akalin HE, Firat M, Serin A: In vitro activity and clinical efficacy of in infections due to Brucella melitensis. Reviews of Infectious Disease 1989, 5(suppl 11):993-994.
• [10]Andriole VT: Clinical overview of the newer 4-quinolone antibacterial agents. The quinolones. London: Academic Press; 1988.
• [11]Doganay M, Aygen B: Use of Ciprofloxacin in treatment of brucellosis. Eur Journal of Clin Microbiol & Infect Dis 1992, 11:74-75.
• [12]Lang R, Raz R, Sacks T, Shapiro M: Failure of prolonged treatment with ciprofloxacin in acute brucellosis. Journal of Antimicrobial Chemotherapy 1990, 6:841-46.
• [13]Al-Sibia MB, Halim MA, el-Shaker MM, Khan BA, Qadri SM: Efficacy of ciprofloxacin for treatment of Brucella melitensis infections. Antimicrob Agents Chemother 1992, 36:150-52.
• [14]Perez-Gorricho B, Ripoll M: Does short-course antibiotic therapy better meet patient expectations? Int J Antimicrob Agents 2003, 21:222-8.
• [15]Agalar C, Usubutun S, Turkyilmaz R: Ciprofloxacin and Rifampicin Versus Doxycyline and Rifampicin in the Treatment of Brucellosis. Eur Journal of Clin Microbiol & Infect Dis 1999, 18:535-38.